###### Implications

-   As a model of human pregnancy, research studies in catheterized fetal sheep have made significant contributions to our understanding of both normal and abnormal fetal development.

-   Owing to the invasive nature of catheterization surgery, effective postoperative analgesia is required.

-   Decisions regarding appropriate analgesia should consider effectiveness in reducing maternal pain and fetal well-being as well as potential impacts upon fetal physiological parameters under investigation.

-   The reporting of analgesic regimes in all research studies should comply with the ARRIVE guidelines.

Sheep as a Model of Human Pregnancy {#s1}
===================================

Studies in sheep have made significant contributions to our understanding of normal and abnormal fetal development, and have enabled scientists and clinicians to answer questions about the etiology and treatment of poor maternal, placental, and fetal health ([@CIT0034]). One fundamental advantage of utilizing sheep as an animal model of human pregnancy is the ability to surgically implant a diverse range of physiological monitoring systems into both maternal and fetal compartments. Implanting indwelling catheters into the maternal and fetal vasculature ([@CIT0033]) enables repetitive materno-fetal blood sampling free from any confounding effects of maternal, and therefore fetal anesthesia. In addition, surgical manipulation of the ovine fetus has provided key foundational knowledge for novel in utero treatment options for conditions such as spina bifida and diaphragmatic hernia. Incredibly rich information on fetal well-being can be captured from a highly dynamic in utero environment under a variety of experimental conditions that cannot be achieved from studies of a human fetus.

While pregnant ewes appear tolerant of abdominal/intrauterine surgery to access the fetus, effective postoperative analgesia is required both from an animal welfare perspective and to reduce the potential confounding effects of pain on the physiological variables under investigation. The effectiveness of postoperative analgesic regimens largely focus on maternal recovery. Whether or not the fetus is sensate, and therefore capable of experiencing pain as we understand it, is difficult to quantify and requires consideration of the physical, emotional, and cognitive aspects of pain perception. The fetus itself may be relatively less perceptive of postsurgical pain than its mother due to the physiological suppression of central nervous system activity by allopregnalone, a metabolite of progesterone, which maintains the fetus in sleeping behavioral states ([@CIT0019]; [@CIT0032]). Although the fetus may respond to painful stimuli, these reactions appear to be mediated via brainstem and subcortical pathways, and do not involve consciousness or awareness of pain ([@CIT0032]). Despite the importance of effective analgesia following surgery to instrument the fetus, we have observed that the type of drug, route of administration, and dosing schedule are often not reported.

In this review, we summarize the most commonly reported analgesics in sheep fetal vascular catheterization surgery ([Table 1](#T1){ref-type="table"}), discuss potential fetal impacts of each drug, and report original research conducted in our laboratory comparing the behavioral response to surgery following administration of two commonly used analgesics. We also provide a discussion of relevant considerations to be made when deciding upon an analgesic regimen for postsurgery analgesia. Importantly, we limit our discussion to systemic maternal administration, which potentially impacts the fetus as well as the mother. Although local or regional analgesia to maternal surgical wounds is also commonplace, it is beyond the scope of this review.

###### 

Dosing regimen for analgesics commonly used systemically in studies utilizing maternal and fetal catheter surgery

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Analgesic            Dose               Route of maternal administration   Dosing schedule                                                                  Mechanism of action           Potential fetal impacts                                                                                         References
  -------------------- ------------------ ---------------------------------- -------------------------------------------------------------------------------- ----------------------------- --------------------------------------------------------------------------------------------------------------- -------------------------------------
  Buprenorphine        10--60 mg kg^−1^   Subcutaneous                       Twice a day for 2 d                                                              µ-Opiod receptor agonist,\    Untested                                                                                                        [@CIT0029], [@CIT0021], [@CIT0030]
                                                                                                                                                              κ-opiod receptor antagonist                                                                                                                   

  Carprofen            1.4 mg kg^−1^      Intramuscular                      Day of surgery and repeated daily as required based on evidence of pain.         Non-specific COX inhibitor    Untested, although possible impacts upon ductus arteriosus patency                                              [@CIT0001], [@CIT0006], [@CIT0043]

  Flunixin meglumine   2.2 mg kg^−1^      Intramuscular                      Day of surgery and repeated daily as required based on evidence of pain.         Non-specific COX inhibitor    Untested, although possible impacts upon ductus arteriosus patency                                              ([@CIT0037], [@CIT0005], [@CIT0003]

  Meloxicam            0.5 mg kg^−1^      Subcutaneous                       Day prior to surgery and repeated daily as required based on evidence of pain.   Selective COX-2 inhibitor     No impact upon fetal hemodynamics or COX expression in fetal tissues                                            [@CIT0041], [@CIT0040]

  Xylazine             50 μg kg^−1^       Intramuscular                      Upon awakening from anesthesia.                                                  α2-adrenergic receptor        Increases myometrial activity, transiently suspends fetal breathing and decreases fetal heart rate and PaO~2~   [@CIT0020], [@CIT0011], [@CIT0045]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Commonly Used Analgesics for Sheep Fetal Catheterization Surgery {#s2}
================================================================

Xylazine {#s3}
--------

Xylazine has been widely used in veterinary medicine and preclinical research studies to induce sedation or as an adjunct to injectable and inhalational anesthetics ([@CIT0028]). Xylazine is also effective in reducing experimentally induced acute, peripheral pain in sheep ([@CIT0036]; [@CIT0015]), and has been used for postoperative maternal analgesia following fetal catheterization surgery, including within our own laboratory ([@CIT0044]; [@CIT0011]). Xylazine is an α2-adrenergic receptor agonist ([@CIT0042]) for which a significant proportion of the antinociceptive effects are mediated via heteroceptors located in the dorsal horn of the spinal cord ([@CIT0026]). However, xylazine has a relatively short half-life of 22 min ([@CIT0013]), and bolus intravenous administration to an adult sheep provides analgesia to mechanical and thermal stimuli for approximately 60 min ([@CIT0036]). There are also well-documented side effects following the use of α2-adrenergic receptor agonists in a range of species, including hypoxemia, bradycardia, and hypotension (reviewed by [@CIT0023]). These effects occur at the higher doses required for sedation and anesthesia, and may not impact hemodynamic or cardiovascular measures at the lower doses used for analgesia ([@CIT0014]). Nevertheless, the potential adverse consequences combined with a lack of sustained analgesic effects raise concerns about the appropriateness of xylazine as a postoperative analgesic.

Buprenorphine {#s4}
-------------

Buprenorphine is a potent analgesic commonly used to alleviate pain in research animals ([@CIT0036]), and has also been used as a maternal analgesic following fetal sheep catheter surgery ([@CIT0030]). As a partial µ-opioid agonist, buprenorphine hyperpolarizes centrally located neurons by opening K^+^ and closing Ca^2+^ channels, thus providing antinociceptive effects for thermal stimuli for up to three and a half hours ([@CIT0050]). However, the analgesic effect following mechanical noxious stimuli in sheep is variable ([@CIT0050]). Following a surgical insult in lambs, buprenorphine is effective in providing short-term analgesia as measured by behavioral responses to pain, but is less effective in reducing physiological responses such as cortisol secretion ([@CIT0038]). Systemic administration to sheep has marked side effects, including agitation, chewing movements, bleating, rapid and frequent head movements, and respiratory depression ([@CIT0036]), and as a scheduled drug, the use, storage and administration of buprenorphine is heavily controlled.

Non-steroidal anti-inflammatory drugs {#s5}
-------------------------------------

Non-steroidal anti-inflammatory drugs (NSAIDs) are also routinely used for postoperative pain management in veterinary medicine ([@CIT0027]). NSAIDs inhibit both major isoforms of the cyclooxygenase (COX) enzyme (i.e., COX-1 and COX-2) and inhibit the processing of arachidonic acid to prostaglandins, thromboxanes, and leukotrienes ([@CIT0048]), although relative inhibition of these isoforms varies between NSAIDs. The therapeutic effects largely result from their inhibition of prostaglandin production via the inducible COX-2 at sites of inflammation, whereas many of the side effects, such as gastrointestinal (GI) ulceration and bleeding, are attributed to inhibition of the constitutive COX-1 isoform (reviewed in [@CIT0004]). Commonly used NSAIDs for maternal analgesia following fetal catheterization surgery include the relatively nonselective COX inhibitors carprofen ([@CIT0001]) and flunixin meglumine ([@CIT0037]). Similarly, the COX-2-- selective NSAID meloxicam has demonstrated efficacy in reducing pain and inflammation following experimentally induced lameness ([@CIT0009]) and provides partial analgesia to lambs following ring castration ([@CIT0039]). Due to its preferential inhibition of COX-2 over COX-1 ([@CIT0012]), meloxicam has a superior tolerance profile for upper GI tract effects in humans ([@CIT0018]). Furthermore, unlike xylazine or buprenorphine, meloxicam does not cause respiratory suppression and can therefore be administered prior to surgery, thus ensuring plasma levels are at their highest at the time of the insult. With a half-life of 14 hr in nonpregnant sheep, the analgesic effects of meloxicam are sustained ([@CIT0046]). However, NSAIDs are used with caution perioperatively in humans due to potential for renal dysfunction ([@CIT0002]), although we are not aware of similar concerns in sheep.

Paracetamol administration has been given postoperatively to sheep recovering from fetal catheterization surgery ([@CIT0031]). Although not an NSAID, paracetamol does suppress prostaglandin production by inhibition of COX. The analgesic properties of paracetamol, however, likely arise at multiple levels in the pain stimulus conduction pathway, including at tissue receptors, spinal cord, thalamus, and the cerebral cortex in which pain sensations are evoked ([@CIT0022]).

Additional Considerations When Administering Analgesics During Pregnancy {#s6}
========================================================================

Analgesic administration to pregnant ewes may have significant direct and indirect consequences for the fetus and may threaten the integrity and/or reproducibility of research outcomes. It is, therefore, important to consider both maternal and fetal effects of analgesia when deciding upon an analgesic regime ([Figure 1](#F1){ref-type="fig"}).

![Considerations when selecting a postoperative analgesic regimen in studies of sheep fetal development.](vfz019f0001){#F1}

Bolus xylazine administration to pregnant ewes increases myometrial activity, suspends fetal breathing, and decreases fetal heart rate and the partial pressure of oxygen (PaO~2~) ([@CIT0020]), although these effects are relatively transient and are unlikely to have long-term impacts upon the fetus. We are unaware of any studies examining the impact of maternal buprenorphine administration upon fetal lamb physiology; however, ex vivo studies of human term placenta suggest that there is low transplacental transfer of buprenorphine to the fetus ([@CIT0035]).

Despite their widespread use and well-documented tolerability in nonpregnant animals, there are major concerns around the use of NSAIDs during pregnancy. Patency of the fetal ductus arteriosus (key to normal fetal cardiorespiratory status) is maintained by circulating prostaglandins derived from the placenta and by the low oxygen tension normally present in the fetus ([@CIT0008]). In humans, it is recommended that NSAIDs are not used in the third trimester of pregnancy ([@CIT0049]) due to inhibition of prostaglandin synthesis increasing the risk of fetal, rather than postnatal, closure of the ductus arteriosus ([@CIT0025]). Whether postoperative NSAID administration to sheep, in the doses required for analgesia, has detrimental impacts upon ductus arteriosus patency is unknown. Both COX-1 and COX-2 are expressed in the fetal sheep ductus arteriosus ([@CIT0007]), and in vitro inhibition of either isoform can cause contraction ([@CIT0007]). Furthermore, infusion of selective COX-2 inhibitors directly into the fetal vasculature (at doses much greater than experienced following maternal analgesic administration) induces contraction of the ductus arteriosus ([@CIT0047]). However, in a sheep model of preterm labor, maternal meloxicam administration does not affect fetal acid--base status, plasma osmolality, arterial pressure, heart rate, or regional blood flow to the fetal kidney, intestine, adrenal glands, or cotyledon ([@CIT0041]). Maternal meloxicam administration also does not affect COX expression in fetal kidney, small intestines, lung, liver, or heart ([@CIT0040]). These results clearly demonstrate that a consideration of fetal impacts is warranted when developing analgesic regimes for preclinical research.

Recent Experience {#s7}
=================

Decisions about postoperative analgesic regimen must consider effectiveness, duration of pain relief, potential side effects, and fetal impacts. Owing to concerns around sustained effectiveness, we transitioned from the use of xylazine analgesia to a regime of subcutaneous administration of meloxicam on the day prior to and following surgery, for all maternal/fetal indwelling catheter procedures conducted in our laboratory from 2017 onwards. Here we retrospectively compare the behavioral impact of meloxicam with xylazine, as assessed by prospective documentation of postoperative clinical condition, including feed intake. Studies using xylazine analgesia (2013--2016) and those using meloxicam analgesia (2017--2018) were all conducted at the South Australian Health and Medical Research Institute (SAHMRI) Preclinical Imaging Research Facility (PIRL), in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (National Health and Medical Research Council 2013), and with approval from appropriate local Animal Ethics Committees.

Merino ewes between 105 and 125 days of gestation (term = 150 ± 3 days of gestation) were housed individually in a 12:12 (light:dark) hr photoperiod with ad libitum access to water. Animals were daily fed 1 kg lucerne chaff (85% dry matter, metabolizable energy content = 8.3 MJ kg^−1^) supplemented with pellets containing straw, cereal, hay, clover, barley, oats, lupins, almond shells, oat husks, and limestone (singletons 300 g, twins 500 g; 89% dry matter, metabolizable energy content = 11.6 MJ kg^−1^). Anesthesia was induced with diazepam (0.3 mg kg^−1^, intravenous) followed by ketamine (7 mg kg^−1^, intravenous), then maintained with 1.5% to 2.5% isoflurane in oxygen. Vascular catheters were implanted into the maternal jugular vein, fetal femoral artery and vein as well as the amniotic cavity as described previously ([@CIT0010]). Fetal catheters were exteriorized through a small incision in the ewe's flank. At surgery, antibiotics were administered intramuscularly to the ewe (3.5 mL of 150 mg mL^−1^ procaine penicillin, 112.5 mg mL^−1^ benzathine penicillin, plus 2 mL of 250 g mL^−1^ dihydrostreptomycin) and fetus (1 mL of 150 mg mL^−1^ procaine penicillin, 112.5 mg mL^−1^ benzathine penicillin, plus 1 mL of 250 g mL^−1^ dihydrostreptomycin). Antibiotics were administered intramuscularly to each ewe for 3 days after surgery and intra-amniotically (5 mL of 100 mg mL^−1^ ampicillin) for 4 days after surgery.

Analgesia and clinical monitoring {#s8}
---------------------------------

Ewes were administered xylazine (20 µg kg^−1^, intramuscular, *n* = 50) upon recovery from anesthesia, or meloxicam (0.5 mg kg^−1^, subcutaneous, *n* = 56) at 1600 hr on both the day prior to and day of surgery. Daily food consumption was determined by weighing daily food offered and residual feed. Routine clinical records were collected for 3 d prior and up to 6 d following surgery by trained animal technicians who were not members of the research group. Ewes were assessed each morning and scored on a scale of 0 to 3 for appetite, drinking, defecation, urination, alertness, and surgical site, where 0 is normal and 3 is severely affected ([Figure 2](#F2){ref-type="fig"}). A total clinical score was calculated as the sum of all scores for each animal and used to determine the appropriate level of monitoring and care as follows: score of ≥2, twice daily monitoring; ≥4, report to principle investigator and animal welfare officer; ≥6, seek veterinary assessment and treat as advised; and ≥10, humane euthanasia followed by post mortem. Total clinical scores and food consumption were analyzed by a linear mixed model to assess effects of treatment (xylazine and meloxicam) and time (day postsurgery) as a repeated measure, with Bonferroni correction for post hoc comparisons at each postsurgical day (IBM SPSS Statistics for Windows, Version 25, Armonk, NY).

![Determination of total clinical score as developed with the SAHMRI Animal Ethics Committee. Ewes are assessed daily by a trained animal technician and scored on a scale of 0 to 3 for each of the indicators as described to generate a total clinical score. Scores \>2 require escalation of monitoring and care, with increased monitoring frequency routinely conducted for at least 24 hr following surgery.](vfz019f0002){#F2}

Results {#s9}
=======

The effect of surgery on total clinical scores in singleton- and twin-bearing ewes depended on the type of analgesia used (surgery vs. analgesic interaction: singleton *P* = 0.003, twin *P* \< 0.001). In singleton-bearing ewes administered xylazine, surgery increased total score at day 1 (1.5 ± 0.4, *P* = 0.001), day 2 (1.4 ± 0.4, *P* = 0.001), and day 3 (1.2 ± 0.4, *P* = 0.036) postsurgery ([Figure 3A](#F3){ref-type="fig"}). In twin-bearing ewes administered xylazine, surgery increased total score at day 1 (1.7 ± 0.4, *P* = 0.001) and day 2 (1.8 ± 0.4, *P* = 0.001) postsurgery ([Figure 3B](#F3){ref-type="fig"}). However, surgery did not alter total clinical scores in either singleton- or twin-bearing ewes administered meloxicam (singleton *P* = 0.616, twin *P* = 0.095).

![Change in total clinical record score (A and B) and food consumption (C and D) compared with presurgical measures following fetal indwelling catheter surgery in ewes administered xylazine (20 µg kg^−1^; given as a single postoperative dose; red circles; singleton, *n* = 36; twin, *n* = 14) or meloxicam (0.5 mg kg^−1^; given preoperatively 16 to 24 hr prior and at surgery; blue squares; singleton, *n* = 36; twin, *n* = 20). Significant differences from baseline are shown by \* in xylazine administered ewes, and \# in meloxicam administered ewes (*P* \< 0.05).](vfz019f0003){#F3}

Similarly, the effect of surgery on food consumption in singleton- and twin-bearing ewes depended on the type of analgesia (surgery vs. analgesic interaction: singleton *P* = 0.04, twin *P* \< 0.001). In singleton-bearing ewes administered xylazine, surgery reduced food consumption at day 1 (−387 ± 91 g, *P* = 0.001), day 2 (−403 ± 93 g, *P* \< 0.001), and day 3 (−293 ± 91 g, *P* = 0.034) postsurgery ([Figure 3C](#F3){ref-type="fig"}). In twin-bearing ewes administered xylazine, surgery reduced food consumption at day 2 (−536 ± 165 g, *P* = 0.034) postsurgery ([Figure 3D](#F3){ref-type="fig"}). In comparison, postsurgery food consumption in ewes administered meloxicam was significantly reduced only at day 4 (−276 ± 77 g, *P* = 0.008) and only in singleton-bearing ewes.

These results demonstrate that with our previous analgesic regimen of postsurgical xylazine administration, ewes experienced an increase in total clinical scores and reduced appetite for up to 3 d postsurgery. In contrast, these clinical indicators were largely unchanged in ewes administered meloxicam. While this suggests meloxicam provides superior analgesic protection to ewes following fetal indwelling catheter surgery, an analysis of quantifiable parameters that directly assess severity of pain, for example, the Sheep Grimace Scale ([@CIT0017]), and plasma cortisol as a marker of the physiological stress response are required to confirm this.

Into the Future {#s10}
===============

In this review, we have discussed the effectiveness and possible complications of analgesics commonly used in sheep fetal catheterization studies. The primary consideration when choosing an analgesic regimen should be effectiveness. Largely this has involved assessment of maternal behavioral and physiological responses to painful stimuli, and the ability of analgesia to mitigate the response. Fetal perceptions of catheterization should also be considered, and whether systemic maternal administration is likely to have any benefit for the fetus. However, unlike the ewe, it is not possible to accurately or directly assess the impact of analgesia on the fetus. Without the surgically implanted monitoring lines, assessment of fetal condition relies on indirect measures (e.g., ultrasound) taken at a point in time that may not be representative or relevant. Nevertheless, considerations such as route of administration, transport across the placenta, and placenta drug metabolism may influence decisions.

Specific analgesic drugs or drug classes may be more or less appropriate depending on the main outcomes of interest. Fetal catheterization studies cannot be ethically or scientifically justified if the analgesic regimen compromises scientific outcomes. Furthermore, the choice of an appropriate analgesic regimen for specific studies will need to consider issues such as comparability with previous work and the need to maintain consistency throughout an experimental series, to avoid the ethical impact of additional animals needed to repeat previous work. Ideally, factors influencing analgesic choice will be considered and changes implemented at the start of a new series of studies. In addition, restrictions on access to, or the personnel allowed to administer, some classes of licensed drugs, may restrict available options.

Finally, critical to any studies involving maternal and fetal surgery is the need to report the analgesic regimen including dose, route of administration and regimen, as prescribed by the ARRIVE guidelines ([@CIT0024]) and required by some journals ([@CIT0016]).
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